Filter by Year:
Press Releases
-
Sep 03, 2024
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
-
Aug 28, 2024
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
-
Aug 08, 2024
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
-
May 28, 2024
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
-
May 22, 2024
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
-
May 20, 2024
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
-
May 06, 2024
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
-
Apr 16, 2024
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
-
Apr 09, 2024
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
-
Apr 05, 2024
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
Displaying 1 - 10 of 87